Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response

International Journal of Gynecological Cancer

Volumn 22, Issue 8, 2012, Pages 1344-1348

  Levy, Tally ^a,b,c   Weiser, Roi ^c,d   Boaz, Mona ^b,e   Shem, Erez Ben ^a,b,c   Golan, Abraham ^b,c   Menczer, Joseph ^a,b,c  

^a Division of Gynecologic Oncology   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e ARIEL UNIVERSITY   (Israel)

Author keywords

Complete clinical response; Ovarian; Primary peritoneal and tubal carcinoma; Recurrence; Rising CA 125 within reference limits

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CYTOREDUCTIVE SURGERY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84867251361     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182691254     Document Type: Article

References (13)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Van der Burg MEL, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol. 1990;1:301-302.
3. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7: 361-364.
4. Cruickshank DJ, Terry PB, Fullerton WT. The potential value of CA125 as a tumour marker in small volume, non-evaluable epithelial ovarian cancer. Int J Biol Markers. 1991;6:247-252.
5. Vergote I, Rustin GJS, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. J Natl Cancer Inst. 2000;92:1534-1535.
6. Wilder JL, Pavlik E, Straughn JM, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol. 2003;89:233-235.
7. Santillan A, Garg R, Zahurak MI, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
8. Liu PY, Alberts DS, Monk BJ, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007;25:3615-3620.
9. Prat A, Parera M, Adamo B, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol. 2009;20:294-297.
10. Rustin GJ, van der Burg ME, Griffin CL, et al. MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
11. Tanner EJ, Chi DS, Eisenhauer EL et al. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time? Gynecol Oncol. 2010;117:336-340.
12. Fleming ND, Cass I, Walsh CS, et al. CA125 surveillance increases optimal respectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 2011;121:249-252.
13. Morris RT, Monk BJ. Ovarian cancer: relevant therapy, not timing, is paramount. Lancet. 2010;376:1120-1122.